Silber 2017.

Methods	Design: parallel group randomized trial Duration of study: December 2014 and September 2015 Follow‐up: 17–21 days
Participants	Country: Ethiopia and Rwanda Setting: community Number included in study: 295 Age: 28 days to 17 years Sex: 143 boys, 152 women Inclusion criteria: not reported Exclusion criteria: not reported Lost at follow‐up: 17 (5.8%) Number positive for A lumbricoides: 167 Number included in review: 167
Interventions	Treatment strategy: screening and treat all included participants Group 1: mebendazole 500 mg single dose (chewable) (n = 86) Group 2: identical placebo (chewable) (n = 81)
Outcomes	Outcomes included:Ascaris cure rates, adverse events Outcomes not included in review: anthelmintic efficacy for T trichiura, plasma concentration of mebendazole
Notes	Diagnostic technique: not reported Funding support: Janssen Research & Development
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "double blind randomized trial."
Allocation concealment (selection bias)	Unclear risk	Details not reported.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical chewable tables of mebendazole and placebo.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	17 (5.8%) participants lost at follow‐up and not included in analysis.
Selective reporting (reporting bias)	Low risk	All stated outcomes were reported.
Other bias	Unclear risk	Project carried out by Janssen Research & Development.